

$HIMS (-4,37 %) and $NOVO B (+2,49 %) have announced a groundbreaking collaboration to make obesity treatment more accessible and affordable in America.
The partnership's first initiative introduces Wegovy through the $HIMS (-4,37 %) -platform, bundled with comprehensive healthcare services for $599 per month.
The offer combines all of Wegovy's dosage strengths with the benefits of a $HIMS (-4,37 %) -membership, including:
- 24/7 care access
- Ongoing clinical support
- Nutritional counseling
- Access to the NovoCare pharmacy
VERY positive for $HIMS (-4,37 %) as it all but negates the entire pessimistic assessment of potential lawsuits.
🚀